Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
None USD 0.00(0%)
Last update at 2024-09-11T10:46:41.618580Z
Market Cap
315.94M

Momentum Score

…

Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
12.75
Low
12.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.91M
Revenue Per Share
0.02
Gross Profit TTM
0.30M
Debt / Equity
28.11
ROE
-1823.07%
Net Debt
3.93M
ROCE
-62.86%
Diluted EPS TTM
-3.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -55.74M -63.74M -38.67M -44.28M -43.71M
Net income -53.68M -61.87M -36.96M -42.65M -41.73M
Selling general administrative - - - 20.90M 24.15M
Gross profit -28.45M -40.51M -24.40M -28.30M -30.67M
Reconciled depreciation -1.48M 8.44M 8.83M 1.55M 1.64M
Ebit -44.23M -48.14M -28.98M -42.53M -42.77M
Ebitda -45.71M -39.70M -20.56M -41.67M -41.85M
Depreciation and amortization -1.48M 8.44M 8.42M 0.86M 0.93M
Operating income -51.92M -60.41M -36.41M -42.39M -42.77M
Other operating expenses 44.58M 50.47M 28.90M 42.48M 42.77M
Interest expense 3.82M 3.32M 2.53M 1.78M 0.94M
Tax provision -2.06M -1.86M -1.71M -1.64M -1.98M
Net interest income -3.82M -3.32M -2.53M -1.78M -0.94M
Income tax expense -2.06M -1.86M -1.71M -1.64M -1.98M
Total revenue 0.37M 2.34M 0.00M 0.00M 0.00M
Total operating expenses 15.76M 7.62M 4.50M 14.18M 12.09M
Cost of revenue 28.82M 42.85M 24.40M 28.30M 30.67M
Total other income expense net -3.82M -3.33M -2.26M -1.89M -0.94M
Net income from continuing ops -53.68M -61.87M -36.96M -42.65M -41.73M
Net income applicable to common shares -53.70M -61.87M -36.96M -42.65M -41.73M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 85.24M 69.08M 59.84M 64.68M 36.83M
Intangible assets - 0.09M 0.02M 0.03M 0.09M
Other current assets 0.00M 0.00M 2.68M 0.00M 0.95M
Total liab 83.27M 82.63M 66.52M 40.21M 29.35M
Total stockholder equity 1.97M -13.55M -6.69M 24.47M 7.48M
Other current liab 5.70M 5.18M 4.41M 3.25M 3.03M
Common stock 0.91M 0.62M 0.52M 0.50M 0.37M
Capital stock 0.91M 0.62M 0.52M 0.50M 0.37M
Retained earnings -68.91M -98.84M -36.96M -230.13M -187.48M
Other liab - 2.31M 0.62M 0.41M 0.30M
Other assets 0.00M 0.00M 0.55M 0.47M -0.00M
Cash 51.43M 39.19M 35.98M 55.51M 25.30M
Total current liabilities 14.87M 13.70M 12.50M 8.60M 10.65M
Current deferred revenue - - -10.09M - -
Net debt 3.93M 12.83M 2.96M -39.09M -20.65M
Short term debt 2.64M 0.13M 0.08M - -
Short long term debt 2.64M 0.13M 0.08M - -
Short long term debt total 55.36M 52.02M 38.94M 16.41M 4.65M
Other stockholder equity 69.97M 84.66M 29.75M 254.09M 194.59M
Property plant equipment - 6.78M 6.41M 5.11M 5.56M
Total current assets 77.76M 61.67M 52.86M 59.06M 30.69M
Net tangible assets - 0.87M 7.80M 38.95M 20.45M
Net receivables 8.90M 8.13M 4.11M 2.94M 4.58M
Long term debt 52.72M 51.89M 38.86M 16.41M 4.65M
Inventory 17.44M 14.34M 9.90M - -
Accounts payable 6.53M 8.39M 8.01M 5.35M 7.62M
Non currrent assets other 0.77M 0.54M 0.55M 0.47M 0.49M
Non current assets total 7.47M 7.41M 6.98M 5.61M 6.14M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.99M 0.01M -0.07M 0.01M -0.01M
Change to liabilities 0.00M 0.39M 2.66M -2.27M 1.79M
Total cashflows from investing activities -2.00M -1.75M -2.30M -0.64M -2.31M
Net borrowings - 10.12M 20.00M 11.45M 11.45M
Total cash from financing activities 68.60M 65.13M 25.81M 71.09M 5.06M
Change to operating activities - 0.19M -1.23M 1.90M -0.77M
Net income -51.92M -61.87M -36.96M -42.65M -41.73M
Change in cash 12.24M 3.21M -19.52M 30.20M 19.23M
Begin period cash flow 39.19M 35.98M 55.51M 25.30M 6.07M
End period cash flow 51.43M 39.19M 35.98M 55.51M 25.30M
Total cash from operating activities -54.38M -60.17M -43.03M -40.24M -38.17M
Issuance of capital stock 69.08M 55.01M 5.81M 0.13M 0.01M
Depreciation -1.48M 8.44M 8.42M 0.86M 0.93M
Other cashflows from investing activities -2.00M -1.80M -1.80M -1.80M -1.80M
Change to inventory - -9.56M -17.42M -0.12M -0.19M
Change to account receivables - -0.46M -0.46M -0.46M -0.46M
Other cashflows from financing activities -0.00M 10.11M 20.00M 70.95M 5.05M
Change to netincome -0.70M 10.08M 10.01M 1.46M 0.95M
Capital expenditures 1.75M 1.76M 2.33M 0.65M 2.29M
Change in working capital - -9.70M -17.01M -0.22M 1.69M
Other non cash items -0.97M 2.96M 2.53M 1.76M 0.94M
Free cash flow -56.12M -61.93M -45.36M -40.89M -40.47M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Carmat SA

Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.

36, avenue de l'Europe, Vélizy-Villacoublay, France, 78140

33 1 39 45 64 50

177

Name Title Year Born
Mr. Stephane Piat CEO & Director 1971
Ms. Pascale d'Arbonneau CFO & Head of investor relations NA
Mr. Eric Richez Sales & Bus. Devel. Director 1961
Mr. Francesco Arecchi Marketing Mang. NA
Ms. Raouia Bouyanzer HR Director NA
Dr. Petrus Jansen Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…